Abbott Q2 2021 Earnings Report
Key Takeaways
Abbott's Q2 2021 results revealed a robust performance, with worldwide sales reaching $10.2 billion, a 39.5% increase on a reported basis and 35.0% organically. Excluding COVID-19 testing-related sales, sales grew 11.3% organically compared to pre-pandemic levels in Q2 2019. The company's EPS guidance for 2021 is $2.75 to $2.95.
Worldwide sales increased by 39.5% on a reported basis and 35.0% on an organic basis.
Excluding COVID-19 testing-related sales, worldwide sales increased 11.3% organically compared to pre-pandemic levels in Q2 2019.
Global COVID-19 testing-related sales were $1.3 billion.
FreeStyle Libre® sales were $904 million, representing 52.5% reported sales growth and 42.9% organic sales growth.
Abbott
Abbott
Forward Guidance
Abbott projects 2021 diluted earnings per share from continuing operations under GAAP of $2.75 to $2.95. Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be $4.30 to $4.50 for full-year 2021.